✦ LIBER ✦

Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer

✍ Scribed by Dick Vos; Peter H. Th. J. Slee; Derek Stevenson; Ray J. Briggs

Publisher: Springer
Year: 1992
Tongue: English
Weight: 291 KB
Volume: 31
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00695998

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of toremifene and its m

Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer

✍ Valerie J. Wiebe; Christopher C. Benz; Irving Shemano; Timothy B. Cadman; Michae 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 433 KB

Effects of tamoxifen on serum lipid and

Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer

✍ Manuel Morales; Norberto Santana; Adela Soria; Alicia Mosquera; José Ordovás; Ja 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 503 KB

Biomonitoring of urinary tamoxifen and i

Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry

✍ Spencer J. Carter; Xing-Fang Li; John R. Mackey; Shanu Modi; John Hanson; Norman 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

The expression of insulin-like growth fa

The expression of insulin-like growth factor and its binding protein mRNA in the endometrium of postmenopausal patients with breast cancer receiving tamoxifen

✍ Timo J. Laatikainen; Eija I. Tomás; Raimo J. Voutilainen 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 2 views

Serum level of cryptic tumor antigens in

Serum level of cryptic tumor antigens in breast cancer patients as determined by two monoclonal antibodies (m85/f36) and its comparison with ca 15-3

✍ Dr. T. Ming; Rodric Constantine; Takuma Nemoto 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 563 KB

An enzyme immunoassay system that measures cryptic epitopes on breast cancer mucinlike antigens (BCM-EIA) was evaluated in a double-blind manner in sera from 58 normal blood donors, 36 sex-and age-matched controls, 36 patients with benign breast diseases, and 47 patients with breast cancer. Two muri

Simultaneous determination of gemcitabin

Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry

✍ Elena Marangon; Federica Sala; Orazio Caffo; Enzo Galligioni; Maurizio D'Incalci 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 1 views

## Abstract Gemcitabine, 2′,2′‐difluoro‐2′‐deoxycytidine (dFdC) is a pyrimidine antimetabolite employed against several human malignancies. It undergoes intracellular activation to the pharmacologically active triphosphate form (dFdCTP) and metabolic inactivation to the metabolite 2′,2′‐difluorodeo